You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 3, 2024

DORYX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Doryx patents expire, and when can generic versions of Doryx launch?

Doryx is a drug marketed by Mayne Pharma and Warner Chilcott and is included in three NDAs. There are four patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in DORYX is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Doryx

A generic version of DORYX was approved as doxycycline hyclate by CARIBE HOLDINGS on November 8th, 1982.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DORYX?
  • What are the global sales for DORYX?
  • What is Average Wholesale Price for DORYX?
Drug patent expirations by year for DORYX
Drug Prices for DORYX

See drug prices for DORYX

Drug Sales Revenue Trends for DORYX

See drug sales revenues for DORYX

Pharmacology for DORYX

US Patents and Regulatory Information for DORYX

DORYX is protected by one US patents.

Patents protecting DORYX

Tabletting process
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma DORYX doxycycline hyclate CAPSULE, DELAYED RELEASE;ORAL 050582-002 Aug 13, 2001 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-002 May 6, 2005 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-006 Dec 19, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DORYX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-002 May 6, 2005 ⤷  Sign Up ⤷  Sign Up
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-006 Dec 19, 2014 ⤷  Sign Up ⤷  Sign Up
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-004 Apr 11, 2013 ⤷  Sign Up ⤷  Sign Up
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-005 Apr 11, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DORYX

See the table below for patents covering DORYX around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2006045152 ⤷  Sign Up
Australia 2005299253 Improved tabletting process ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.